Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$141.31 - $287.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)540.89K
Market Cap
$28.53B
Enterprise Value$22.17B
Total Cash (Recent Filing)$13.90M
Total Debt (Recent Filing)$13.84M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 07, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.13
Shares Outstanding98,910,760
10 Day Avg. Volume562,550
30 Day Avg. Volume540,891
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.06
Price to Cash Flow (P/CF)89.50
P/FCF Ratio72.30
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.89
Enterprise Value/Ebitda-55.80
Forecast
1Y Price Target
$320.21Price Target Upside30.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Investment PotentialBeiGene shares represent a unique investment opportunity to own a growing global biotech name, especially given the recent selloff.
Revenue GrowthBrukinsa is on track to generate significant revenue for the company, indicating strong market performance and financial health.
Strategic FocusBeiGene's management shows decisiveness by focusing on assets with the highest probability of success, enhancing the potential for commercial success.
Bears Say
Clinical Trial PerformanceThe AMPLIFY trial, Phase 3 study evaluating fixed-duration treatment with acalabrutinib combined with venetoclax, failed to meet expectations.
Market CompetitionBrukinsa taking over the U.S. BTKi market with significant sales growth compared to its competitor.
---
Ownership Overview
Currently, No data available
---
ONC FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $141.31 and its highest was $287.88 in the past 12 months.
What is BeiGene’s market cap?
BeiGene’s market cap is $28.53B.
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is May 07, 2025 which is in 9 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on Mar 27, 2025. The company reported -$1.43 earnings per share for the quarter, missing the consensus estimate of -$1.012 by -$0.418.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -0.55.
How many shares outstanding does BeiGene have?
BeiGene has 98,910,760 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$1.43 in its last earnings report, missing expectations of -$1.012. Following the earnings report the stock price went up 4.655%.
Which hedge fund is a major shareholder of BeiGene?
Currently, no hedge funds are holding shares in ONC
---
BeiGene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$320.21 (30.75% Upside)
$320.21 (30.75% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 908.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $190.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.84%
12-Months-Change
Fundamentals
Return on Equity
-18.77%
Trailing 12-Months
Asset Growth
2.06%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
---
ONC Company Deck
---
ONC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and market leadership for BRUKINSA, along with robust R&D productivity. However, challenges remain in the competitive landscape and in achieving desired outcomes with fixed duration treatments. Overall, the positives significantly outweigh the negatives.Read More>---
ONC Stock 12 Month Forecast
Average Price Target
$320.21
▲(30.75% Upside)
Technical Analysis
---